|
Volume 272, Number 47, Issue of November 21, 1997
pp. 29636-29642
Creatine Phosphate, Not ATP, Is Required for 3 End Cleavage of
Mammalian Pre-mRNA in Vitro*
(Received for publication, July 14, 1997, and in revised form, September 17, 1997)
Yutaka
Hirose
and
James L.
Manley
From the Department of Biological Sciences, Columbia University,
New York, New York 10027
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
The poly(A) tail of a mammalian mRNA is
generated by endonucleolytic cleavage and poly(A) addition. Previous
studies conducted with nuclear extracts suggested an ATP requirement
for the cleavage step. We have reexamined the cofactor requirement,
initially with the SV40 late pre-mRNA, which requires for cleavage
four protein factors, cleavage and polyadenylation specificity factor,
cleavage stimulation factor, cleavage factor I, and cleavage factor II. Using highly purified preparations of these factors, which lacked detectable creatine phosphokinase and ATPase activities, creatine phosphate (CP) was, surprisingly, found to be sufficient to promote efficient cleavage. Although other phosphate compounds substituted poorly or not at all for CP, another phosphoguanidine, arginine phosphate, was fully functional. Notably, ATP was neither necessary nor
sufficient, and could in fact inhibit the reaction. Treatment of the
purified factors with hexokinase plus glucose (to deplete any
contaminating ATP) was without effect, as was addition of EDTA. Using
32P-labeled CP, we found that neither hydrolysis of
CP nor phosphate transfer from CP occurred during the cleavage
reaction. CP also allowed cleavage of the adenovirus 2 L3 pre-mRNA.
However, in this case, ATP both enhanced the reaction and influenced
the precise site of cleavage, perhaps reflecting the requirement of
poly(A) polymerase for cleavage of this RNA. These results indicate
that ATP is not essential for 3 pre-mRNA cleavage and that CP
or a related compound can function as a necessary
cofactor.
INTRODUCTION
All eukaryotic mRNAs, with the exception of major histone
mRNAs, have a poly(A) tail at their 3 end. The process generating the poly(A) tail, referred to as 3 end formation, involves
endonucleolytic cleavage of the precursor RNA followed by the
sequential addition of adenylate residues. 3 end formation is an
essential step in the maturation of pre-mRNAs, and it appears to be
coupled with other events in the nucleus, including transcription
termination (1-3) and mRNA splicing (4-6). The resulting poly(A)
tail has been suggested to play important roles in mRNA stability
(reviewed in Ref. 7) and translation (reviewed in Ref. 8). Alternate usage of polyadenylation sites can regulate gene expression through changing the capacity of coding or noncoding sequences in the 3 region
of mRNA (9-10) (reviewed in Ref. 11).
Although the cleavage and poly(A) addition reactions are tightly
coupled in vivo, development of in vitro systems
made it possible to study these reactions separately and to purify
factors required for each step (for reviews, see Refs. 12 and 13). Cleavage can be assayed by blocking poly(A) polymerase
(PAP)1 activity with either
EDTA or chain-terminating ATP analogs, such as 3 dATP, whereas poly(A)
addition independent of cleavage can be studied by using
"precleaved" RNA substrates. In mammalian cells, two RNA sequence
elements are essential for efficient 3 end formation. One is the
highly conserved hexanucleotide AAUAAA located 10-30 nucleotides
upstream of the cleavage site, and the other is a less conserved GU- or
U-rich sequence that lies just downstream of the cleavage site (for
review, see Ref. 14). Accurate and efficient cleavage requires five
protein factors: cleavage and polyadenylation specificity factor
(CPSF), cleavage stimulation factor (CstF), two cleavage factors (CFI
and CFII), and, in many cases, PAP (15-18). CPSF consists of at least
three subunits (160, 100, and 73) and likely a fourth (30 kDa) that is
nonessential in vitro (19-22). CstF is composed of three
subunits (77, 64, and 50 kDa) (23-26). CPSF and CstF can specifically
and cooperatively interact with AAUAAA and the downstream GU-rich
sequence in the precursor RNA, respectively (21, 22, 27-30), and thus
they likely can specify the poly(A) site. CFI (16) has been purified from HeLa cells and appears also to be a multisubunit factor (31), although the roles of both CFI and CFII in cleavage have not been well
defined. PAP, a single polypeptide of ~85 kDa (32, 33), is
dispensable for cleavage of SV40 late pre-mRNA in vitro
but is required for efficient cleavage of other substrates (Ref. 15). Following cleavage, CPSF, PAP, and poly(A) binding protein II participate in poly(A) addition (34-36). CstF, CFI, and CFII are not
necessary for this reaction in vitro, although whether these factors dissociate from the complex at this stage is not clear.
Although the RNA sequences and protein factors responsible for 3
end formation have been well studied, cofactor requirements for the
reaction have been examined only with relatively crude extracts (for
review, see Refs. 37 and 38). Early experiments conducted with
unfractionated nuclear extracts suggested that ATP is a necessary
cofactor for the cleavage reaction (39, 40) and for formation of
polyadenylation-specific complexes (40-43). However, several
observations have confused the issue. First, the cleavage reaction was
found to proceed in the absence of divalent cation and the presence of
EDTA (39, 44), which would not be expected for an ATP-requiring
reaction. Second, the addition of creatine phosphate (CP), commonly
used to regenerate ATP by phosphate transfer from CP to ADP (catalyzed
by creatine phosphokinase (CPK)), was shown to be sufficient for
cleavage in the absence of exogenously added ATP and divalent cation
(15). These observations could reflect an unusual mechanism of ATP
regeneration from endogenous ATP/ADP in the crude protein fractions or
indicate that ATP is not in fact necessary for cleavage. We therefore
reexamined the cofactor requirement for in vitro cleavage
using highly purified factors. Here we present evidence that CP can in
fact function as a necessary and sufficient cofactor for efficient
in vitro cleavage. Although ATP is not required, it can
function as either an inhibitor or an activator of the reaction,
depending on the specific substrate, and can also affect the precise
cleavage site in PAP-dependent cleavage. Possible
mechanisms of CP-activated cleavage are discussed.
EXPERIMENTAL PROCEDURES
Materials
Creatine phosphate was purchased from Sigma,
Calbiochem, and Boehringer Mannheim. Arginine phosphate was from Sigma.
32P-Labeled creatine phosphate (2.3 × 107
cpm/µg) was enzymatically synthesized from [ -32P]ATP
(4500 Ci/mmol; ICN) and creatine (Sigma) by creatine phosphokinase (Boehringer Mannheim) and then purified by MonoQ FPLC.
Proteins
Partial purification of CPSF, CFI, and CFII
from HeLa cell nuclear extracts was performed as described (16). CPSF
(0.12 µg/µl) was further purified by heparin-5PW FPLC. CFI (0.4 µg/µl) and CFII (0.15 µg/µl) were MonoS fractions (16). CstF
(0.15 µg/µl) was also a MonoS fraction (purity greater than 90%;
Ref. 23). CFI was further purified by phenyl-Superose FPLC (PS-CFI; 0.12 µg/µl). Alternatively, the MonoQ low salt fraction (mixture of
CFI and CFII; Ref. 16) was fractionated by heparin-5PW FPLC, MonoS
FPLC, and heparin-5PW FPLC (HP-CFI; 0.15 µg/µl). CFII was further
purified by MonoS (MSS-CFII; 50 ng/µl), or the MonoQ low salt
fraction was fractionated by heparin-5PW FPLC (HP-CFH; 40 ng/ml).
Histidine-tagged recombinant bovine PAP (50 ng/µl) was purified from
Escherichia coli (gift of K. G. K. Murthy). All protein
fractions were stored in Buffer D (20 mM HEPES-NaOH, pH 7.9, 20% glycerol, 50 mM
(NH4)2SO4, 0.2 mM EDTA,
0.5 mM dithiothreitol, and 0.5 mM
phenylmethylsulfonyl fluoride). Details of the CFI and CFII
purification procedures will be described
elsewhere.2
RNA Substrates and in Vitro Cleavage
Assay
32P-labeled pre-mRNAs were prepared by SP6
RNA polymerase (Promega) from linearized plasmids pG3SVL-A and pG3L3-A,
which contain the SV40 late site and adenovirus 2 L3 poly(A) site,
respectively (15). A standard 12.5-µl cleavage reaction mixture
contained 0.25 µl of CstF; 2.0 µl of CPSF; 1.75 µl of CFI; 2.0 µl of CFII; 0.25 µl of either Buffer D (for SV40 pre-mRNA) or
recombinant bovine PAP (for L3 pre-mRNA); 10 mM
HEPES-NaOH, pH 7.9; 10% glycerol; 25 mM
(NH4)2SO4; 0.1 mM EDTA;
0.25 mM dithiothreitol; 0.25 mM phenylmethylsulfonyl fluoride; 2.5% polyvinyl alcohol; 0.2-0.5 ng of
substrate RNA; 500 ng of E. coli tRNA; and 2 mM
EDTA, 0.5 mM MgCl2, or no divalent cation as
indicated, plus the indicated amounts of CP, ATP, or other potential
cofactors. Reaction mixtures were incubated for 90-120 min at
30 °C, and purified RNAs were fractionated on 5% polyacrylamide,
8.3 M urea gels.
ATP Depletion and Thin-layer Chromatography
Reaction
mixtures (30 µl) containing 25 µl of protein mixture (8 µl of
CPSF, 1 µl of CstF, 7 µl of CFI, 8 µl of CFII, and 1 µl of
Buffer D), 2.5 mM MgCl2,, 2 mM
glucose, 0.6 unit of hexokinase (Boehringer Mannheim), and 0.6 µCi of
[ -32P]ATP were incubated for 10 min at 30 °C.
Polyethyleneimine-cellulose TLC plates (Selecto Scientific) were washed
by elution with deionized water and dried before use. Aliquots (1 µl)
taken from reaction mixtures at various time points were diluted with
20 mM EDTA to 20 µl and frozen on dry ice until use.
After thawing, diluted samples were spotted on the prepared
polyethyleneimine-cellulose TLC plates and developed in 1 M
formic acid and 0.5 M LiCl (Figs. 5A and
6C) or in 0.25 M LiCl (Fig. 6B).
32P-Labeled compounds were visualized by
autoradiography.
Fig. 5.
Depletion of possible endogenous ATP does not
affect cleavage. Standard reaction mixtures containing 4 nM [ -32P]ATP (as a tracer to monitor ATP
depletion), cleavage factors, hexokinase, 2 mM glucose, and
2.5 mM MgCl2 were incubated at 30 °C. After
10 min, reaction mixtures were brought to standard cleavage conditions
by adding RNA substrate plus or minus 4 mM EDTA and either
40 mM CP (lanes 1-4) or 1 mM ATP
(lanes 5-8) and was further incubated at 30 °C.
Reactions were stopped at the indicated times, and aliquots were
analyzed either directly by chromatography on polyethyleneimine-cellulose using 1 M formic acid and 0.5 M LiCl as solvent (A) or by fractionation on 5%
polyacrylamide-8.3 M urea gels after extraction of RNAs
(B). The position of each phosphate compound (A)
or 5 and 3 RNA cleavage products (B) are indicated on the
left.
[View Larger Version of this Image (41K GIF file)]
Fig. 6.
CP is not hydrolyzed and ATP is not generated
during cleavage. Time course of cleavage reaction (A)
and fate of 32P-labeled CP (B and C)
under standard cleavage conditions. Reaction mixtures containing
32P-labeled SV40 pre-mRNA, trace amount of
32P-labeled CP, 40 mM unlabeled CP, and 2 mM EDTA were incubated at 30 °C. Reactions were stopped
at the indicated times, and aliquots were analyzed either by
fractionation on 5% polyacrylamide-8.3 M urea gels after
extraction of RNAs (A) or directly by chromatography on
polyethyleneimine-cellulose using either 0.25 M LiCl
(B) or 1 M formic acid and 0.5 M
LiCl (C) as solvent. The position of each phosphate compound
(B and C) or 5 and 3 RNA cleavage product (A) is indicated on the right.
[View Larger Version of this Image (31K GIF file)]
RESULTS
Creatine Phosphate Is Required for Efficient Cleavage
Our
previous experiments using a relatively crude preparation of 3
processing factors demonstrated that efficient cleavage could be
detected in the presence of CP without added ATP, whereas addition of
ATP alone did not allow cleavage (15). This observation suggested
either that the protein fraction employed contained high ATPase levels,
as well as sufficient CPK to regenerate ATP, or that CP functioned as a
necessary cofactor for cleavage. We therefore reinvestigated the
requirement of CP and/or ATP for 3 cleavage using protein factors that
were more purified than those used in the previous experiments. We
first assayed in vitro cleavage reconstituted with an RNA
precursor containing the SV40 late poly(A) signal (SV40 pre-mRNA)
with highly purified CstF and CPSF and partially purified CFI and CFII
prepared from HeLa cell nuclear extracts under standard cleavage
conditions, which included 2 mM EDTA (see "Experimental
Procedures"). Importantly, these factors all lacked detectable CPK
(measured as in Ref. 45) and ATPase (measured by hydrolysis of
[ -32P]ATP) activities when assayed under cleavage
reaction conditions, whereas in the presence of Mg2+, CPK
activity was again undetectable, and only trace levels of ATPase were
observed (data not shown). Fig.
1A shows that, as observed
previously with less purified factors, addition of 20 mM CP
alone was sufficient to allow efficient cleavage (lane 3), whereas no phosphate compound (lane 1) or ATP alone (1 mM) (lane 4) did not result in detectable
cleavage. In fact, the presence of both ATP and CP in the reaction
mixture reduced cleavage efficiency (compare Fig. 1, lanes 2 and 3, and see below). Fig. 1B shows that
cleavage efficiency increased according to the concentration of CP.
Cleavage was greatly reduced at concentrations below 10 and above 60 mM CP (data not shown).
Fig. 1.
Creatine phosphate (CP) can be a sufficient
cofactor for efficient 3 end cleavage. 32P-Labeled
SV40 pre-mRNA substrate was incubated in a standard cleavage
reaction mixture containing CPSF, CstF, CFI, CFII, and 2 mM
EDTA for 90 min at 30 °C in the presence of (A) no
phosphate compound (lane 1), 20 mM CP
(lane 3), 1 mM ATP (lane 4), or both (lane 2) or (B) in the presence of the indicated
amounts of CP. Processed RNAs were isolated and fractionated on 5%
polyacrylamide-8.3 M urea gels. Lanes M and
Pre indicate size marker and precursor RNA, respectively.
The positions of size markers are indicated (in nucleotides) on the
left, and the positions of 5 and 3 cleavage products are
indicated by arrows on the right.
[View Larger Version of this Image (41K GIF file)]
We next examined whether a number of other compounds could function as
cofactors in the cleavage reaction. Creatine, NaCl, sodium
pyrophosphate, and a number of nucleotide tri-, di- or monophosphates
were unable to allow cleavage over a wide range of concentrations (Fig.
2A and data not shown; note
that GTP reproducibly caused degradation of the substrate). On the
other hand, NaPO4 and to a somewhat lesser extent
KPO4 did allow cleavage (Fig. 2B). However, the
optimal efficiency of cleavage observed was lower by a factor of six
than that observed with CP, as determined by PhosphorImager analysis.
Importantly, the same high concentrations of these compounds were
required to induce cleavage as was observed with CP. This is
significant because NaPO4 can be a trace contaminant of CP,
but since such high amounts were necessary, it cannot be the active
component in CP (concentrations lower than those shown in Fig.
2B were inactive; data not shown).
Fig. 2.
Certain other phosphate compounds can
substitute for CP. Cleavage of SV40 pre-mRNA was assayed under
standard reaction conditions, as described in the legend to Fig. 1, in
the presence of no addition ( ) or the indicated phosphate compounds
(concentration was 20 mM for CP, 1 mM for
others) (A); increasing amounts of CP (lanes
2-4), KH2PO4 + K2HPO4 (lanes 5-7), or
NaH2HPO4 + Na2HPO4 (lanes 8-10) (B); or increasing amounts of CP or
AP (C). Concentration of each compound is indicated above
each lane. The position of cleavage products are indicated as in Fig.
1.
[View Larger Version of this Image (38K GIF file)]
Given the high concentration of CP required for cleavage, we were
concerned about the possibility that a contaminant in the CP
preparation other than inorganic phosphate might be the actual cofactor
(see also below). To address this, we tested four different preparations of CP obtained from three different sources (one was
prepared synthetically, whereas the others were prepared enzymatically; see "Experimental Procedures") and found that all four preparations of CP behaved identically (data not shown). The Tris and sodium salts
of CP also gave indistinguishable results (data not shown). We also
tested whether another phosphoguanidine compound, arginine phosphate
(AP), which exists only in invertebrates (reviewed in Ref. 46), could
substitute for CP in the cleavage assay. Strikingly, AP also activated
cleavage, and it did so as efficiently as CP (Fig. 2C). This
implies that the phosphoguanido group may be an important structural
motif of the cofactor. Importantly, the fact that AP can substitute for
CP further argues against the possibility that the CP requirement in
fact reflects an ATP requirement, through the activity of undetectable
contaminating CPK in the purified factors, because AP can not be used
as a substrate by CPK (47).
In the above experiments, we utilized highly purified preparations of
CPSF and CstF, whereas the CFI and CFII fractions were less pure
(although, as mentioned above, they were free of detectable CPK and
ATPase). To provide additional evidence that contaminants in the
protein fractions were not in some way responsible for the CP effect,
both CFI and CFII were subjected to additional purification steps (see
"Experimental Procedures"), and two different preparations of each
were used in cleavage assays, as above. Under standard reaction
conditions (a solution containing 2 mM EDTA and no ATP), CP
was again found to be essential for cleavage, activating the reaction
in a concentration-dependent manner, nearly identical to
the results observed with the less pure cleavage factors (Fig.
3).
Fig. 3.
CP can activate cleavage reconstituted with
highly purified cleavage factors. Cleavage of SV40 pre-mRNA
was assayed under standard reaction conditions, in which CFI and CFII
were replaced by CFI further purified by phenyl-Superose FPLC
(PS-CFI) and CFII further purified by second MonoS
(MSS-CFII), respectively (lanes 1-4), or by CFI
purified by heparin-5PW (HP-CFI) and CFII purified by
heparin-5PW (HP-CFII), respectively (lanes 5-8)
(see "Experimental Procedures"), in the presence of 2 mM EDTA and increasing amount of CP. Concentration of CP is
indicated above each lane. The position of cleavage products are
indicated as in Fig. 1.
[View Larger Version of this Image (45K GIF file)]
ATP Is Not Required for Cleavage
The above results suggest
that CP, not ATP, can be a necessary and sufficient cofactor for
efficient 3 cleavage in vitro. However, given the
unexpected nature of this finding, we investigated more extensively the
possible role of ATP in 3 cleavage of the SV40 pre-mRNA. We first
tested the effect of increasing concentrations of exogenous ATP on
cleavage. Fig. 4A shows that
ATP concentrations as high as 10 mM did not allow
detectable cleavage in the presence of either 0.5 mM
MgCl2 (lanes 2-4) or 2 mM EDTA
(lanes 7-9), whereas CP alone allowed efficient cleavage
under both reaction conditions (lanes 5 and 10).
As shown above (Fig. 1A), cleavage in the presence of both
ATP and CP appeared less efficient than cleavage in the presence of CP
alone. We therefore examined the effect of increasing ATP
concentrations on cleavage activated by 40 mM CP. Fig.
4B shows that ATP indeed inhibited cleavage effected by CP
in a concentration-dependent manner in the presence of
either 0.5 mM MgCl2 (lanes 2-4) or
2 mM EDTA (lanes 6-8). In contrast, high
concentrations of EDTA (up to 8 mM) had no significant
effect on cleavage efficiency (Fig. 4C, lanes 1-4). These
findings strengthen the conclusions that divalent cations are not
required for cleavage and that ATP is not only not required but can in
fact be inhibitory.
Fig. 4.
ATP but not EDTA inhibits cleavage.
Cleavage of SV40 pre-mRNA was assayed under standard reaction
conditions in the presence of 0.5 mM MgCl2
(lanes 1-5), 2 mM EDTA (lanes
6-10), increasing amounts of ATP (lanes 2-4 and
7-9), 40 mM CP (lanes 5 and
10), or H2O (lanes 1 and
6) (A); 40 mM CP (all
lanes), 0.5 mM MgCl2 (lanes
1-4), 2 mM EDTA (lanes 5-8), or
increasing amounts of ATP (lanes 2-4 and 6-8)
(B); 40 mM CP (lanes 1-4),
increasing amounts of EDTA (lanes 2-4), or H2O
(lane 1) (C). Concentrations of ATP (A
and B) or EDTA (C) are indicated above each lane.
The position of cleavage products are indicated as in Fig. 1.
[View Larger Version of this Image (32K GIF file)]
We next examined the possibility that a bound form of ATP, perhaps
tightly associated with a purified factor(s), might participate in
cleavage. To this end, cleavage was assayed using factors treated with
hexokinase and glucose to remove any endogenous ATP. Depletion of
endogenous ATP by conversion to glucose 6 phosphate was monitored via
addition of trace amounts of [ -32P]ATP and was
analyzed by TLC. After incubation of purified factors with hexokinase
and glucose for 10 min in the presence of MgCl2, the
exogenous ATP was entirely depleted (Fig.
5A, lanes 1 and 5).
EDTA and substrate pre-mRNA were then added, and reaction mixtures
were incubated for the times indicated in Fig. 5, after which RNA
products and ATP were both analyzed. Although no labeled ATP was
generated at any time during the incubation (Fig. 5A, lanes
2-4 and lanes 6-8), efficient cleavage was detected
when CP was added (Fig. 5B, lanes 2-4), but not when ATP
was added (Fig. 5B, lanes 6-8). Identical results (not
shown) were obtained in the absence of added EDTA, which would allow
the hexokinase to remain active throughout the incubation. Taken
together, the above results indicate that 3 cleavage occurs
efficiently in the absence of ATP.
CP Is Not Hydrolyzed during the Cleavage Reaction
CP has a
large free energy of hydrolysis ( 10.3 kcal/mol; reviewed in Ref. 46)
and, as suggested above, is a necessary cofactor for efficient 3
cleavage. These points raise the possibility that CP could function as
a direct energy donor during the cleavage reaction. To examine this, we
tested whether hydrolysis of CP occurs during the cleavage reaction.
32P-Labeled CP was prepared by enzymatic reaction from
[ -32P]ATP and creatine and purified as described under
"Experimental Procedures." Hydrolysis of CP during the cleavage
reaction was monitored by removing small aliquots from reaction
mixtures containing trace amounts of 32P-labeled CP and 40 mM unlabeled CP at the times indicated in Fig.
6 and then analyzing the fate of the CP
by TLC. Whereas efficient cleavage proceeded during the incubation
(Fig. 6A), neither hydrolyzed inorganic phosphate (Fig.
6B) nor ATP, conceivably generated by transferring the
phosphate group from CP to possible endogenous ADP (Fig.
6C), was detected. These results suggest that CP is neither
an energy donor for cleavage nor a phosphate source to produce ATP.
This latter finding further excludes the possibility that the observed
CP requirement reflects ATP regeneration by CPK contamination in the
purified factors. Also, SDS gel electrophoresis of reaction mixtures
following incubation with labeled CP failed to provide any evidence of
protein phosphorylation (results not shown).
CP Can Enhance Cleavage of Adenovirus L3 Pre-mRNA
We next
wished to determine whether our findings could be extended to other
pre-mRNAs, which, unlike SV40 late, require PAP for cleavage. We
therefore examined the substrate specificity of the CP effect on
cleavage by using a pre-mRNA containing the adenovirus L3 poly(A)
signal (48), purified factors as above, and recombinant bovine PAP (see
"Experimental Procedures"). Fig. 7
shows that no cleavage was detected in the absence of CP (lanes 1 and 5), but processing was observed as the
concentration of CP was increased (lanes 2-4 and
6-8). However, in this case, cleavage was inefficient, and
addition of 1 mM ATP with CP greatly enhanced cleavage
efficiency (compare lanes 2-4 and lanes 6-8).
Note, however, that reaction mixtures contained no divalent cation,
suggesting that the role of ATP is likely unusual. It is also
noteworthy that assays with ATP yielded two different size upstream
cleavage products (Fig. 7, lanes 6-8), whereas assays
without ATP yielded only the longer one (Fig. 7, lanes
2-4). These results suggest that ATP can influence the precise
site of endonucleolytic cleavage. Such heterogeneity in cleavage site
specification with L3 pre-mRNA has also been observed by other
groups in the presence of 3 dATP (49, 50). We also observed similar
heterogeneity in the presence of 3 dATP, but in this case, the shorter
upstream cleavage product was less prominent than in the presence of
ATP (data not shown). Taken together, our data suggest that CP also
functions as a necessary cofactor for cleavage of L3 pre-mRNA, but
ATP enhances cleavage efficiency and affects the local choice of
cleavage sites.
Fig. 7.
ATP can enhance PAP-dependent
cleavage, but CP is still necessary. 32P-Labeled L3
pre-mRNA was incubated in standard cleavage reaction mixtures
containing CPSF, CstF, CFI, CFII, and PAP in the presence of increasing
amounts of CP and either H2O (lanes 1-4) or 1 mM ATP (lanes 5-8) at 30 °C and analyzed as
in Fig. 1. Concentration of CP is indicated above each lane. Precursor
RNA (Pre), size markers, and cleavage products are indicated
as in Fig. 1.
[View Larger Version of this Image (51K GIF file)]
DISCUSSION
ATP has until now been thought to be an essential cofactor for
endonucleolytic cleavage of pre-mRNAs containing 3 end processing signals. In contrast, CP has been assumed to act as a reservoir for ATP
regeneration during the cleavage reaction. CP is used for this purpose
in many ATP-requiring reactions in which contaminating ATPases might
otherwise deplete the ATP pools, including, for example, such
complicated processes as transcription, translation, and splicing.
Using highly purified 3 processing factors, we have shown that CP does
not function in 3 end formation to regenerate ATP. Instead, it is able
to function by itself as a necessary and sufficient cofactor for the
reaction. Importantly, the ability of CP to act as a high energy donor
is not required, and indeed, our data have shown that no energy source
is required for RNA 3 cleavage. Although our experiments have
established that ATP is not necessary, they have also shown that it can
affect cleavage either positively or negatively, dependent on the
substrate.
ATP appears to be required for 3 cleavage in yeast extracts (51).
Whether or not this reflects a significant difference between the yeast
and mammalian catalytic machinery is not clear. However, recent studies
have revealed unexpected similarities between several mammalian and
yeast polyadenylation factors (reviewed in Ref. 52), and it could be
that the ATP requirement reflects the absence of CP and related
compounds in yeast.
CP is a member of the phosphagen family, which consists of high energy
phosphorylated guanidine compounds that are believed to provide
temporary energy buffers in tissues with high energy demands (reviewed
in Ref. 53). CPK catalyzes the reversible transfer of phosphate groups
between CP and ADP (46). Several lines of evidence exclude the
possibility that the observed CP requirement in the 3 cleavage
reaction in fact reflects an ATP requirement through generation of ATP
by undetected CPK activity in the purified factors. First, we were not
able to detect any CPK activity in any of the purified factors. Second,
AP could substitute for CP, even though AP exists only in invertebrates and cannot be a substrate of CPK (47). Third, cleavage proceeds normally even in the presence of 8 mM EDTA, although CPK
requires a divalent cation for catalytic activity. Fourth, during
cleavage, phosphate transfer from 32P-labeled CP to
possible endogenous ADP was not detected. Finally, ATP depletion (by
glucose and hexokinase) was without effect on cleavage. Since four
different preparations of commercially available CP and one preparation
of AP gave identical results, we believe that CP or a related
guanidinophosphate compound is required for efficient cleavage.
However, our findings that high concentrations of CP (20-60
mM) are necessary for optimal cleavage and that similar concentrations of sodium phosphate allow a lower level of cleavage leave some question as to the identity of the physiologically relevant
cofactor. Our data have shown conclusively, however, that the factor is
not ATP.
Is it even reasonable to consider the possibility that CP, at
concentrations of ~40 mM, is the physiologically relevant
cofactor? Although the answer to this question is probably no (the only tissue where this high a level of CP has been documented is skeletal muscle (54, 55)), many other tissues (e.g. brain, smooth
muscle, and kidney), have been shown to have CP concentrations of 5-10 mM (56). Thus, if CP can perform its essential function in
polyadenylation (see below) at this level in vivo, then it
would appear that the concentration of CP could be adequate. But
another requirement is that CP be in the nucleus. Although the bulk of
CPK is found in the cytoplasm, a number of studies have found
significant levels of the enzyme in the nucleus (57-59). In addition,
although to our knowledge, the intracellular localization of CP has not
been measured, diffusion through the nuclear pores would likely allow accumulation in the nucleus (60).
Given that our data have established that the role of CP in
polyadenylation is not to function as an energy source, what could it
be doing to facilitate 3 cleavage? The earliest steps in the reaction
have been well studied; they involve specification of the poly(A) site
by the cooperative interaction of CstF and CPSF with the pre-mRNA
(20, 27, 28). A variety of experiments suggest that this interaction,
which is frequently measured by the UV-cross-linking of the CstF-64
polypeptide to the pre-mRNA, is independent of CP (or ATP) (20, 23,
61-64). Therefore, it is likely that an interaction involving CFI
and/or CFII requires CP. These factors are not well characterized,
although CFI appears to be a heterotrimer, and all three subunits can
be UV-cross-linked to RNA (31). We propose that CP is able to
facilitate a conformational change important for the function of one or
both of these factors. Interestingly, our early studies are consistent
with the idea that CPSF, CstF, CFI, and CFII all coexist in a single
large complex (15), and it is thus possible that a conformational
change within this complex is facilitated by CP or a related compound.
Also supporting the involvement of CFI and/or CFII, when a cruder
fraction containing both these factors (MonoQ; see Ref. 16) was
employed with CstF and CPSF, a low but significant level of cleavage
could be detected in the absence of CP (and
ATP).3 Although we do not
have a clear explanation for this phenomenon, it was not observed when
cruder fractions of CstF or CPSF were used, and thus it again
implicates CFI and/or II as the target of CP.
Another possibility is that CP (or AP) does not in fact play any direct
role in 3 end formation in vivo and functions in vitro by mimicking another component. An intriguing possibility is
that this might be an unknown phosphoprotein, perhaps containing phosphoarginine. Although rare, phosphoarginine is known to exist in
eukaryotic proteins (65). By this model, the high concentrations of CP
required allow it to be recognized by a component of the polyadenylation machinery that naturally recognizes a phosphoprotein. Alternatively, CP (or AP) might bind directly to the RNA, influencing its structure and thereby facilitating cleavage. However, attempts to
detect an interaction between [32P]CP and unlabeled
substrate RNA (SV40 late and AdL3) were unsuccessful.3
Furthermore, neither Mg2+ nor spermidine, which are known
to influence RNA structure, had any affect on cleavage of the SV40 late
pre-mRNA.
Our data have ruled out a requirement for ATP in 3 cleavage. However,
they also show that ATP can influence the reaction, either positively
or negatively, dependent on the pre-mRNA substrate. How does this
occur? We suggest the possibility that the inhibitory effect is due to
competition between CP and ATP. Given our lack of understanding of how
CP functions, it is not possible to comment on the details of this
putative competition, or on the possible physiological significance of
the inhibition. Indeed, given that the SV40 late pre-mRNA is
unusual in its lack of a requirement of PAP for cleavage, it could be
that the enhancement of cleavage, observed with the AdL3 pre-mRNA,
is most relevant. The sequences within the SV40 RNA that confer PAP
independence are limited to nine bases surrounding the cleavage site
(48); it may be that CP facilitates interaction of cleavage factors
with this region, whereas for most pre-mRNAs, PAP and ATP are also
required for optimal cleavage. It is also notable that ATP, in
addition, affects the precise site of cleavage in the AdL3 RNA.
Interestingly, a possibly related phenomenon was observed over a decade
ago by Sperry and Berget (66). These authors observed that in nuclear extract, an SV40 early pre-mRNA (which requires PAP) was cleaved 18-20 bases downstream of the authentic cleavage site when ATP was
omitted from reaction mixtures. This apparently aberrant cleavage appeared to be catalyzed by the normal polyadenylation machinery, as
judged by its poly(A) signal dependence, and was suppressed by ATP in a
concentration-dependent manner. We believe that both the
enhancement of cleavage and the switch in site selection resulting from
ATP are mediated by PAP. Perhaps the processing complex that assembles
when PAP contains bound ATP is different from the complex that
assembles in the absence of ATP. We do not know whether ATP hydrolysis
is required for these effects, but we suspect that it is not, as our
experiments were performed in the absence of divalent cation. It is
intriguing to suggest that other treatments that affect PAP activity
(e.g. phosphorylation; Ref. 67) could also influence
cleavage efficiency or site selection. Future work may elucidate this
type of regulation.
To summarize, our studies have shown that contrary to expectation,
endonucleolytic 3 cleavage of mammalian pre-mRNAs does not require
energy. Creatine phosphate can function as a necessary and sufficient
cofactor, but CP hydrolysis does not occur. Finally, ATP can influence
the reaction quantitatively and qualitatively but is not essential.
FOOTNOTES
*
This work was supported by National Institutes of Health
Grant GM 28983.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed.
1
The abbreviations used are: PAP, poly(A)
polymerase; CPK, creatine phosphokinase; FPLC, fast protein liquid
chromatography; AP, arginine phosphate; CPSF, cleavage and
polyadenylation specificity factor; CstF, cleavage stimulation factor;
CFI, cleavage factor I; CFII, cleavage factor II.
2
Y. Hirose, unpublished data.
3
Y. Hirose and J. L. Manley, unpublished
data.
ACKNOWLEDGEMENTS
We are grateful to Y. Takagaki for providing
plasmids. We thank Y. Takagaki, K. G. K. Murthy, and J. Dahlberg for helpful discussions and suggestions and X. H. Shi, Y. Chen, and C. Shin for assistance in the preparation of nuclear
extracts.
REFERENCES
-
Whitelaw, E., and Proudfoot, N.
(1986)
EMBO J.
5,
2915-2922
[Medline]
[Order article via Infotrieve]
-
Logan, J., Falck-Pedersen, E., Darnell, J. E., and Shenk, T.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
8306-8310
[Abstract/Free Full Text]
-
Connelly, S., and Manley, J. L.
(1988)
Genes Dev.
2,
440-452
[Abstract/Free Full Text]
-
Niwa, M., Rose, S. D., and Berget, S. M.
(1990)
Genes Dev.
4,
1552-1559
[Abstract/Free Full Text]
-
Boelens, W. C., Jansen, E. J. R., van Venrooij, W. J., Stripecke, R., Mattaj, I. W., and Gunderson, S. I.
(1993)
Cell
72,
881-892
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lutz, C. S., Murthy, K. G. K., Sheck, N., O'Connor, J. P., Manley, J. L., and Alwine, J. C.
(1996)
Genes Dev.
10,
325-337
[Abstract/Free Full Text]
-
Caponigo, G., and Parker, R.
(1995)
Genes Dev.
9,
2421-2432
[Abstract/Free Full Text]
-
Tarun, S. Z., and Sachs, A. B.
(1995)
Genes Dev.
9,
2997-3007
[Abstract/Free Full Text]
-
Foulkes, N. S., Schlotter, F., Pevet, P., and Sassone-Corsi, P.
(1993)
Nature
362,
264-267
[CrossRef][Medline]
[Order article via Infotrieve]
-
Takagaki, Y., Seipelt, R. L., Peterson, M. L., and Manley, J. L.
(1996)
Cell
87,
941-952
[CrossRef][Medline]
[Order article via Infotrieve]
-
Proudfoot, N.
(1996)
Cell
87,
779-781
[CrossRef][Medline]
[Order article via Infotrieve]
-
Manley, J. L.
(1995)
Curr. Opin. Genet. Dev.
5,
222-228
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wahle, E., and Keller, W.
(1996)
Trends Biochem. Sci.
21,
247-251
[CrossRef][Medline]
[Order article via Infotrieve]
-
Proudfoot, N.
(1991)
Cell
64,
671-674
[CrossRef][Medline]
[Order article via Infotrieve]
-
Takagaki, Y., Ryner, L., and Manley, J. L.
(1988)
Cell
52,
731-742
[CrossRef][Medline]
[Order article via Infotrieve]
-
Takagaki, Y., Ryner, L., and Manley, J. L.
(1989)
Genes Dev.
3,
1711-1724
[Abstract/Free Full Text]
-
Christofori, G., and Keller, W.
(1989)
Mol. Cell. Biol.
9,
193-203
[Abstract/Free Full Text]
-
Gilmartin, G. M., and Nevins, J. R
(1989)
Genes Dev.
3,
2180-2189
[Abstract/Free Full Text]
-
Bienroth, S., Wahle, E., Satler-Crazzolara, C., and Keller, W.
(1991)
J. Biol. Chem.
266,
19768-19776
[Abstract/Free Full Text]
-
Murthy, K. G. K., and Manley, J. L.
(1992)
J. Biol. Chem.
267,
14804-14811
[Abstract/Free Full Text]
-
Murthy, K. G. K., and Manley, J. L.
(1995)
Genes Dev.
9,
2672-2683
[Abstract/Free Full Text]
-
Jenny, A., Minvielle-Sebastia, L., Preker, P. J., and Keller, W.
(1996)
Science
274,
1514-1517
[Abstract/Free Full Text]
-
Takagaki, Y., Manley, J. L., MacDonald, C. C., Wilusz, J., and Shenk, T.
(1990)
Genes Dev.
4,
2112-2120
[Abstract/Free Full Text]
-
Takagaki, Y., MacDonald, C. C., Shenk, T., and Manley, J. L.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1403-1407
[Abstract/Free Full Text]
-
Takagaki, Y., and Manley, J. L.
(1992)
J. Biol. Chem.
267,
23471-23474
[Abstract/Free Full Text]
-
Takagaki, Y., and Manley, J. L.
(1994)
Nature
372,
471-474
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wilusz, J., Shenk, T., Takagaki, Y., and Manley, J. L.
(1990)
Mol. Cell. Biol.
10,
1244-1248
[Abstract/Free Full Text]
-
Gilmartin, G. M., and Nevins, J. R.
(1991)
Mol. Cell. Biol.
11,
2432-2438
[Abstract/Free Full Text]
-
MacDonald, C. C., Wilusz, J., and Shenk, T.
(1994)
Mol. Cell. Biol.
14,
6647-6654
[Abstract/Free Full Text]
-
Takagaki, Y., and Manley, J. L.
(1997)
Mol. Cell. Biol.
17,
3907-3914
[Abstract]
-
R
egsegger, U., Beyer, K., and Keller, W.
(1996)
J. Biol. Chem.
271,
6107-6113
[Abstract/Free Full Text]
-
Raabe, T., Bollum, F., and Manley, J. L.
(1991)
Nature
353,
229-234
[CrossRef][Medline]
[Order article via Infotrieve]
-
Wahle, E., Martin, G., Schlitz, E., and Keller, W.
(1991)
EMBO J.
10,
215-219
[Medline]
[Order article via Infotrieve]
-
Wahle, E.
(1991)
Cell
66,
759-768
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sheets, M. D., and Wickens, M.
(1989)
Genes Dev.
3,
1401-1412
[Abstract/Free Full Text]
-
Bienroth, S., Keller, W., and Wahle, E.
(1993)
EMBO J.
12,
585-594
[Medline]
[Order article via Infotrieve]
-
Wahle, E., and Keller, W.
(1992)
Annu. Rev. Biochem.
61,
419-440
[Medline]
[Order article via Infotrieve]
-
Wahle, E.
(1995)
Biochim. Biophys. Acta
1261,
183-194
[Medline]
[Order article via Infotrieve]
-
Moore, C. L., and Sharp, P. A.
(1985)
Cell
41,
845-855
[CrossRef][Medline]
[Order article via Infotrieve]
-
Zhang, Z., and Cole, C. N.
(1987)
Mol. Cell. Biol.
7,
3277-3286
[Abstract/Free Full Text]
-
Skolnik-David, H., Moore, C. L., and Sharp, P. A.
(1988)
Genes Dev.
1,
672-682
[Abstract/Free Full Text]
-
Moore, C. L., Skolnik-David, H., and Sharp, P. A.
(1988)
Mol. Cell. Biol.
8,
226-233
[Abstract/Free Full Text]
-
Stefano, J. E., and Adams, D. E.
(1988)
Mol. Cell. Biol.
8,
2052-2062
[Abstract/Free Full Text]
-
Zarkower, D., Stephenson, P., Sheets, M. D., and Wickens, M.
(1986)
Mol. Cell. Biol.
6,
2317-2323
[Abstract/Free Full Text]
-
Oliver, I. T.
(1955)
Biochem. J.
61,
116-122
[Medline]
[Order article via Infotrieve]
-
Lyzlova, S. N., and Stefanov, V. E.
(1991)
Phosphagen Kinases, pp. 1-20, CRC Press, Boca Raton, FL
-
Ennor, A. H., and Morrison, J. F.
(1958)
Physiol. Rev.
38,
631-674
[Free Full Text]
-
Ryner, L. C., Takagaki, Y., and Manley, J. L.
(1989)
Mol. Cell. Biol.
9,
1759-1771
[Abstract/Free Full Text]
-
Gilmartin, G. M., McDevitt, M. A., and Nevins, J. R.
(1988)
Genes Dev.
2,
578-587
[Abstract/Free Full Text]
-
Prescott, J. C., and Falck-Pedersen, E.
(1992)
J. Biol. Chem.
267,
8175-8181
[Abstract/Free Full Text]
-
Zhao, J., Kessler, M. M., and Moore, C. L.
(1997)
J. Biol. Chem.
272,
10831-10838
[Abstract/Free Full Text]
-
Manley, J. L., and Takagaki, Y.
(1996)
Science
274,
1481-1482
[Free Full Text]
-
Wallimann, T., Wyss, M., Brdczka, D., Nicoly, K., and Eppenberger, H. M.
(1992)
Biochem. J.
281,
21-40
-
Beis, I., and Newsholme, E. A.
(1975)
Biochem. J.
152,
23-32
[Medline]
[Order article via Infotrieve]
-
Kushmerick, M. J., Moerland, T. S., and Wiseman, R. W.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7521-7525
[Abstract/Free Full Text]
-
Iyengar, M. R.
(1984)
J. Muscle Res. Cell Motil.
5,
527-534
[CrossRef][Medline]
[Order article via Infotrieve]
-
Koons, S. J., Eckert, B. S., and Zobel, C. R.
(1982)
Exp. Cell Res.
140,
401-409
[CrossRef][Medline]
[Order article via Infotrieve]
-
Cande, W. Z.
(1983)
Nature
304,
557-558
[CrossRef][Medline]
[Order article via Infotrieve]
-
Manos, P., and Edmond, J.
(1992)
J. Comp. Neurol.
326,
273-282
[CrossRef][Medline]
[Order article via Infotrieve]
-
Manos, P., and Bryan, G. K.
(1993)
Dev. Neurosci.
15,
271-279
[Medline]
[Order article via Infotrieve]
-
Wilusz, J., and Shenk, T.
(1988)
Cell
52,
221-228
[CrossRef][Medline]
[Order article via Infotrieve]
-
Moore, C. L., Chen, J., and Whoriskey, J.
(1988)
EMBO J.
7,
3159-3169
[Medline]
[Order article via Infotrieve]
-
Gilmartin, G. M., Fleming, E. S., Oetjen, J., and Graveley, B. R.
(1995)
Genes Dev.
9,
72-83
[Abstract/Free Full Text]
-
Gilmartin, G. M., Hung, S-L., Dezazzo, J. D., Fleming, E. S., and Imperiale, M. J.
(1996)
J. Virol.
70,
1775-1783
[Abstract]
-
Matthews, H. R.
(1995)
Pharmacol. Ther.
67,
323-350
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sperry, A. O., and Berget, S. M.
(1986)
Mol. Cell. Biol.
6,
4734-4741
[Abstract/Free Full Text]
-
Colgan, D. F., Murthy, K. G. K., Prives, C., and Manley, J. L.
(1996)
Nature
384,
282-285
[CrossRef][Medline]
[Order article via Infotrieve]
Volume 272, Number 47,
Issue of November 21, 1997
pp. 29636-29642
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Ryan, A. Khleborodova, J. Pan, and X. P. Ryan
Small molecule activators of pre-mRNA 3' cleavage
RNA,
March 1, 2009;
15(3):
483 - 492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. E. Kleiman, F. Wu-Baer, D. Fonseca, S. Kaneko, R. Baer, and J. L. Manley
BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II
Genes & Dev.,
May 15, 2005;
19(10):
1227 - 1237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Dominski, X.-c. Yang, M. Purdy, E. J. Wagner, and W. F. Marzluff
A CPSF-73 Homologue Is Required for Cell Cycle Progression but Not Cell Growth and Interacts with a Protein Having Features of CPSF-100
Mol. Cell. Biol.,
February 15, 2005;
25(4):
1489 - 1500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Uguen and S. Murphy
3'-Box-dependent processing of human pre-U1 snRNA requires a combination of RNA and protein co-factors
Nucleic Acids Res.,
June 1, 2004;
32(10):
2987 - 2994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. RYAN, O. CALVO, and J. L. MANLEY
Evidence that polyadenylation factor CPSF-73 is the mRNA 3' processing endonuclease
RNA,
April 1, 2004;
10(4):
565 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ryan, K. G. K. Murthy, S. Kaneko, and J. L. Manley
Requirements of the RNA Polymerase II C-Terminal Domain for Reconstituting Pre-mRNA 3' Cleavage
Mol. Cell. Biol.,
March 15, 2002;
22(6):
1684 - 1692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Topalian, S. Kaneko, M. I. Gonzales, G. L. Bond, Y. Ward, and J. L. Manley
Identification and Functional Characterization of Neo-Poly(A) Polymerase, an RNA Processing Enzyme Overexpressed in Human Tumors
Mol. Cell. Biol.,
August 15, 2001;
21(16):
5614 - 5623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wyss and R. Kaddurah-Daouk
Creatine and Creatinine Metabolism
Physiol Rev,
July 1, 2000;
80(3):
1107 - 1213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hirose and J. L. Manley
RNA polymerase II and the integration of nuclear events
Genes & Dev.,
June 15, 2000;
14(12):
1415 - 1429.
[Full Text]
|
 |
|

|
 |

|
 |
 
F. E. Kleiman and J. L. Manley
Functional Interaction of BRCA1-Associated BARD1 with Polyadenylation Factor CstF-50
Science,
September 3, 1999;
285(5433):
1576 - 1579.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Zhao, L. Hyman, and C. Moore
Formation of mRNA 3' Ends in Eukaryotes: Mechanism, Regulation, and Interrelationships with Other Steps in mRNA Synthesis
Microbiol. Mol. Biol. Rev.,
June 1, 1999;
63(2):
405 - 445.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|